News >

Treatment Approaches Evolving in Recurrent Ovarian Cancer

Caroline Seymour
Published: Monday, May 14, 2018

Dennis R. Scribner Jr, MD

Dennis R. Scribner Jr, MD
Recurrence marks a significant shift in the treatment of patients with ovarian cancer, in which it changes from a focus on cure to a focus on effective management, says Dennis R. Scribner Jr, MD. While PARP inhibitors have demonstrated impressive efficacy and tolerability and have helped streamline the process, there are many facets of effective care.

State of the Science Summit™ on Ovarian Cancer, Scribner, clinical associate professor, University of Arizona School of Medicine, Arizona Oncology, discussed the elements and evolution of treatment for patients with recurrent ovarian cancer.

OncLive: How would you define the current state of ovarian cancer?

Scribner: Our focus has been on developing clinical trials that will help women extend their lives and reduce adverse events (AEs). It’s difficult once patients recur, but we have several different therapeutic options that allow us to manage these patients for many years.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication